Chronic rhinosinusitis with nasal polyps (CRSwNP)

Active Ingredient: Depemokimab

Indication for Depemokimab

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Depemokimab is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.

For this indication, competent medicine agencies globally authorize below treatments:

100 mg once every 6 months

For:

Dosage regimens

Subcutaneous, 100 milligrams depemokimab, once every 6 months.

Detailed description

Depemokimab is intended for long-term treatment. A decision to continue the therapy should be made at least annually based on the patient's level of disease control.

The recommended dose of depemokimab is 100 mg administered subcutaneously once every 6 months.

Missed dose

If a dose is missed, it should be administered as soon as possible. If the missed dose is taken 1 month or longer after the scheduled dose, the 6-monthly injection schedule should be resumed from the date when the missed dose was given.

Dosage considerations

For self-administration the recommended injection sites are the abdomen or thigh, except for the 5 cm around the navel. A caregiver can also inject the solution into the upper arm. It should not be injected into areas where the skin is bruised, tender, erythematous, or hardened.

Active ingredient

Depemokimab

Depemokimab targets human IL-5 with a binding affinity of 10.5 pM, thereby blocking the binding to the IL-5 receptor alpha expressed on the cell surface with picomolar potency (IC50 4 pM) in vitro. IL-5 is a pleiotropic cytokine with established impact on eosinophils and other immune and structural cells. In severe asthma, inhibition of IL-5 has demonstrated an improvement in epithelial integrity, mucus plugging and reduction in tissue remodelling. However, the mechanism of action has not been definitively established.

Read more about Depemokimab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.